Drugs / GSK945237
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01039610 | Nov 2009 → Aug 2010 | bacterial infectious disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT00517673 | Jul 2007 → Sep 2008 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK945237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00517673 ↗ |
| Action | Inhibit | “GSK945237 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics.” NCT01039610 ↗ |
| Modality | Small molecule | — CHEMBL3793226 ↗ |
| Route | Oral | “Single Oral Doses of GSK945237” NCT00517673 ↗ |